MedTrace Logo

Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria

NCT02118428 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2019-05-10

Study results available
· View outcomes & findings →

Summary

The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.

Conditions

Interventions

DEVICE

Mirasol-treated Whole Blood

Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood

BIOLOGICAL

Untreated Whole Blood

Transfusion with untreated fresh Whole Blood

Sponsors & Collaborators

  • Terumo BCTbio

    lead INDUSTRY

Principal Investigators

  • Shirley Owusu-Ofori, MD · Komfo Anokye Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02118428 on ClinicalTrials.gov